This announcement is a separate document:
アステラス製薬：米国食品医薬品局、アステラス製薬がゾルベツキシマブの生物製剤ライセンス申請を再提出したことを認め、新しい措置日を設定
Astellas Pharma: US Food and Drug Administration acknowledges that Astellas Pharma has re-submitted a biologics license application for zolbetuximab and sets a new date for action
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.